Neoadjuvant therapy: what are the lessons so far?

Area of Science:

• Oncology
• Breast Cancer Research
• Clinical Trials

Background:

• Neoadjuvant chemotherapy is increasingly used for high-risk breast cancer.
• Accurate assessment of treatment response is crucial for patient outcomes.
• Current methods for predicting treatment benefit require refinement.

Purpose of the Study:

• To review recent advancements in neoadjuvant chemotherapy for high-risk breast cancer.
• To evaluate the utility of pathologic complete response (pCR) as a surrogate for long-term survival.
• To discuss strategies for managing patients who do not achieve pCR and future clinical trial directions.

Main Methods:

• Review of current literature and clinical trial data on neoadjuvant chemotherapy in breast cancer.
• Analysis of the prognostic value of pathologic complete response (pCR).
• Discussion of translational biomarker utility and future clinical trial designs.

Main Results:

• Diagnosis of pathologic complete response (pCR) can avert poor prognosis in high-risk breast cancer.
• The surrogacy of pCR for long-term survival remains uncertain.
• Translational biomarker studies have not effectively identified patients likely to benefit from treatment.
• Prognostic assessment for non-pCR patients is key for risk stratification and trial enrollment.

Conclusions:

• Optimizing neoadjuvant chemotherapy requires better prediction of treatment response.
• Further investigation is needed to validate pCR surrogacy and identify predictive biomarkers.
• Future clinical trials should focus on non-pCR patients and de-escalation of locoregional treatment where appropriate.